JP2018527308A - ナノ粒子組成物のためのバイオマーカー - Google Patents

ナノ粒子組成物のためのバイオマーカー Download PDF

Info

Publication number
JP2018527308A
JP2018527308A JP2017568138A JP2017568138A JP2018527308A JP 2018527308 A JP2018527308 A JP 2018527308A JP 2017568138 A JP2017568138 A JP 2017568138A JP 2017568138 A JP2017568138 A JP 2017568138A JP 2018527308 A JP2018527308 A JP 2018527308A
Authority
JP
Japan
Prior art keywords
mtor
individual
activating
cancer
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527308A5 (enExample
Inventor
ニール ピー． デサイ，
ニール ピー． デサイ，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー, アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2018527308A publication Critical patent/JP2018527308A/ja
Publication of JP2018527308A5 publication Critical patent/JP2018527308A5/ja
Priority to JP2021105535A priority Critical patent/JP2021169457A/ja
Priority to JP2023013778A priority patent/JP2023071656A/ja
Priority to JP2025026646A priority patent/JP2025097987A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017568138A 2015-06-29 2016-06-29 ナノ粒子組成物のためのバイオマーカー Pending JP2018527308A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021105535A JP2021169457A (ja) 2015-06-29 2021-06-25 ナノ粒子組成物のためのバイオマーカー
JP2023013778A JP2023071656A (ja) 2015-06-29 2023-02-01 ナノ粒子組成物のためのバイオマーカー
JP2025026646A JP2025097987A (ja) 2015-06-29 2025-02-21 ナノ粒子組成物のためのバイオマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186309P 2015-06-29 2015-06-29
US62/186,309 2015-06-29
PCT/US2016/040196 WO2017004264A1 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021105535A Division JP2021169457A (ja) 2015-06-29 2021-06-25 ナノ粒子組成物のためのバイオマーカー

Publications (2)

Publication Number Publication Date
JP2018527308A true JP2018527308A (ja) 2018-09-20
JP2018527308A5 JP2018527308A5 (enExample) 2019-08-08

Family

ID=57609078

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017568138A Pending JP2018527308A (ja) 2015-06-29 2016-06-29 ナノ粒子組成物のためのバイオマーカー
JP2021105535A Pending JP2021169457A (ja) 2015-06-29 2021-06-25 ナノ粒子組成物のためのバイオマーカー
JP2023013778A Pending JP2023071656A (ja) 2015-06-29 2023-02-01 ナノ粒子組成物のためのバイオマーカー
JP2025026646A Pending JP2025097987A (ja) 2015-06-29 2025-02-21 ナノ粒子組成物のためのバイオマーカー

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021105535A Pending JP2021169457A (ja) 2015-06-29 2021-06-25 ナノ粒子組成物のためのバイオマーカー
JP2023013778A Pending JP2023071656A (ja) 2015-06-29 2023-02-01 ナノ粒子組成物のためのバイオマーカー
JP2025026646A Pending JP2025097987A (ja) 2015-06-29 2025-02-21 ナノ粒子組成物のためのバイオマーカー

Country Status (10)

Country Link
US (3) US20180177771A1 (enExample)
EP (1) EP3313381A4 (enExample)
JP (4) JP2018527308A (enExample)
KR (2) KR20240144442A (enExample)
AU (3) AU2016285727B9 (enExample)
CA (1) CA2990703C (enExample)
HK (1) HK1254398A1 (enExample)
IL (2) IL256326B2 (enExample)
MX (2) MX2017016519A (enExample)
WO (1) WO2017004264A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525549A (ja) * 2019-03-19 2022-05-17 アブラクシス バイオサイエンス， エルエルシー 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与
JP2023500391A (ja) * 2019-11-11 2023-01-05 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
JP2023546357A (ja) * 2020-10-06 2023-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ベネトクラクス－抵抗性急性骨髄性白血病の対象特異的治療

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
WO2019140257A1 (en) * 2018-01-11 2019-07-18 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing and treating prostate cancer
AU2019239953B2 (en) * 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
KR20210024471A (ko) * 2018-05-22 2021-03-05 아브락시스 바이오사이언스, 엘엘씨 폐고혈압을 치료하기 위한 방법 및 조성물
CN111187834B (zh) * 2019-01-08 2021-01-22 中国科学院上海营养与健康研究所 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
WO2022186673A1 (ko) * 2021-03-05 2022-09-09 전남대학교산학협력단 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘
WO2024215799A1 (en) * 2023-04-11 2024-10-17 Leapfrog Bio, Inc. Pi3k inhibitors for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520289A (ja) * 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221042B (zh) * 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
EP3225697A3 (en) * 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
WO2014144451A2 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Biomarkers for response to rapamycin analogs
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520289A (ja) * 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, 2010, VOL.21, PP.1834-1838, JPN6020021090, ISSN: 0004575111 *
INT. J. CANCER, 2012, VOL.132, PP.1711-1717, JPN6020021089, ISSN: 0004575110 *
NATURE CELL BIOLOGY, 2002, VOL.4, NO.9, PP.648-657, JPN6020021085, ISSN: 0004575109 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525549A (ja) * 2019-03-19 2022-05-17 アブラクシス バイオサイエンス， エルエルシー 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与
JP2023500391A (ja) * 2019-11-11 2023-01-05 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
JP2023546357A (ja) * 2020-10-06 2023-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ベネトクラクス－抵抗性急性骨髄性白血病の対象特異的治療

Also Published As

Publication number Publication date
AU2016285727A1 (en) 2018-02-01
MX2017016519A (es) 2018-08-16
EP3313381A4 (en) 2019-02-27
IL256326B2 (en) 2024-09-01
JP2021169457A (ja) 2021-10-28
US20180177771A1 (en) 2018-06-28
AU2021290200B2 (en) 2024-05-02
WO2017004264A1 (en) 2017-01-05
CA2990703C (en) 2024-04-30
IL256326A (en) 2018-02-28
KR20240144442A (ko) 2024-10-02
US20250152563A1 (en) 2025-05-15
AU2016285727B2 (en) 2021-09-23
AU2016285727B9 (en) 2021-09-30
US20230080409A1 (en) 2023-03-16
KR102708679B1 (ko) 2024-09-24
JP2025097987A (ja) 2025-07-01
IL256326B1 (en) 2024-05-01
IL312318A (en) 2024-06-01
AU2024204661A1 (en) 2024-07-25
HK1254398A1 (zh) 2019-07-19
JP2023071656A (ja) 2023-05-23
KR20180019230A (ko) 2018-02-23
CA2990703A1 (en) 2017-01-05
AU2021290200A1 (en) 2022-01-20
EP3313381A1 (en) 2018-05-02
MX2023013010A (es) 2023-11-15

Similar Documents

Publication Publication Date Title
AU2021290200B2 (en) Biomarkers for nanoparticle compositions
JP2018527308A5 (enExample)
JP7738612B2 (ja) 類上皮細胞腫瘍を処置する方法
US20240009323A1 (en) Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
JP2018521057A5 (enExample)
JP2023500391A (ja) ナノ粒子組成物のためのバイオマーカー
EA045904B1 (ru) Способы лечения эпителиоидноклеточных опухолей

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210226

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210406

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210625

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210625

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210726

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210727

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210827

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210831

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220607

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230117

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20230117

C609 Written withdrawal of request for trial/appeal

Free format text: JAPANESE INTERMEDIATE CODE: C609

Effective date: 20230414